Fractional CO2 Laser Fenestration and Steroid Delivery in HS Lesions

• Status: Not yet recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Assess the efficacy of fractional ablative CO2 therapy combined with topical steroids in HS patients with Hurley stage I or stage II disease.

Hidradenitis suppurativa (HS) is a chronic, oftentimes debilitating inflammatory skin condition that presents with painful lesions in intertriginous areas of the body. The reported prevalence of HS in the U.S. is around 1-4%. Medical therapies, which typically consist of topical or systemic antibiotics, hormone- regulating drugs, and immunomodulators, are initially used to control the disease but HS can be recalcitrant to these modalities in the long-term. Optimizing management of mild-moderate HS is crucial to prevent disease progression and improve patients' quality of life.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Southern California
• Treatments: Triamcinolone

Criteria

Inclusion Criteria:

• 18 years of age or older with a diagnosis of HS for at least 6 months

• Subjects who provide informed consent to undergo the procedure

• Patients with mild to moderate HS (Hurley stage I or stage II)

• Must not have been using topical or systemic therapies for 2 weeks prior to starting treatment on the affected area

• The use of antiseptic washes and intralesional steroid injections for acute lesions (rescue therapy) will be allowed

Exclusion Criteria:

• Under the age of 18

• Pregnant women

• Severe HS (Hurley stage III)

• Using topical or systemic medications within the 2 weeks prior to starting therapy

• History of adverse reactions to laser resurfacing or steroids

• Other diseases besides HS which require ongoing systemic therapies

• Active infection within the treatment area